BARCELONA, June 13 /CNW/ - New data presented at the EULAR meeting
(European League Against Rheumatism) demonstrate that MabThera's (rituximab)
effectiveness in relieving patients of the distressing symptoms of rheumatoid
arthritis (RA) is sustained or further improved with subsequent courses of
treatment, as is the number of patients achieving remission(1). Importantly,
the safety profile of MabThera remained unchanged in patients who had received
as many as seven courses of treatment at 6-12 month intervals.
